TrialBlood2021

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.

Ranjana H Advani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.